Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2012, 5(4), 384-397; doi:10.3390/ph5040384
Review

Stroke Prevention in Atrial Fibrillation: Latest Clinical Trials and Guidelines

1, 2, 3 and 4,*
Received: 15 March 2012; in revised form: 16 March 2012 / Accepted: 28 March 2012 / Published: 5 April 2012
(This article belongs to the Special Issue Anticoagulants)
View Full-Text   |   Download PDF [139 KB, uploaded 24 April 2012]
Abstract: Atrial Fibrillation (AF) is the most common sustained arrhythmia and 1/6 strokes is attributed to AF. The cornerstone of treatment remains maintaining sinus rhythm or appropriate ventricular rate control in addition to prevention of stroke. Oral anticoagulation therapy (OAC) with vitamin K antagonists (VKAs) has been the gold standard for almost 50 years and a significant reduction in the risk of stroke in patients with AF has been demonstrated. Nonetheless, only 50% of patients with guideline recommendations for OAC treatment actually receive VKAs and half of these will discontinue therapy within 3 to 5 years with only another half achieving therapeutic ranges more than 50% of the time. The aforementioned limitations in addition with frequent blood monitoring have prompted the development of a series of new OAC therapies. The present review focuses on the current pharmacological management for stroke prevention in patients with AF based on current and emerging evidence.
Keywords: atrial fibrillation; anticoagulants; stroke; prevention atrial fibrillation; anticoagulants; stroke; prevention
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Armaganijan, L.; Patel, D.; Dietrich, C.; Morillo, C.A. Stroke Prevention in Atrial Fibrillation: Latest Clinical Trials and Guidelines. Pharmaceuticals 2012, 5, 384-397.

AMA Style

Armaganijan L, Patel D, Dietrich C, Morillo CA. Stroke Prevention in Atrial Fibrillation: Latest Clinical Trials and Guidelines. Pharmaceuticals. 2012; 5(4):384-397.

Chicago/Turabian Style

Armaganijan, Luciana; Patel, Dimpi; Dietrich, Cristiano; Morillo, Carlos A. 2012. "Stroke Prevention in Atrial Fibrillation: Latest Clinical Trials and Guidelines." Pharmaceuticals 5, no. 4: 384-397.



Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert